Speaker |
Presentation Title |
Link to Presentation |
Jonathan Himmelfarb, University of Washington |
Renal transporters, kidney disease and toxicity |
Not Available |
Ronald Oude Elferink, Academic Medical Center Amsterdam |
Hepatic phospholipid and bile acid transport deficiencies: therapeutic/clinical implications |
|
Jeffrey Miner, Ardea Biosciences |
Gout and uric acid; from disease to transporters to therapy |
|
Ken Korzekwa, Temple University |
Modeling intracellular concentrations with in vitro imaging and liver perfusion studies |
|
Kim Brouwer, University of North Carolina, Chapel Hill |
Imaging Studies with the Transporter Probe 99mTc-Mebrofenin Reveal Altered Hepatic Exposure in Patients with Non-Alcoholic Steatohepatitis (NASH) |
|
Yuichi Sugiyama, RIKEN |
Is prediction of tissue exposure from in vitro data using PBPK modeling possible? Confirmation by PET imaging to study the clinical disposition of membrane transporter substrates |
|
Adrian Ray, Gilead Sciences |
New developments in renal drug transport |
|
Jashvant Unadkat, University of Washington |
OATP2B1: in vitro, proteomic, and clinical PK relevance in GI and liver |
|
Yan Zhang, Incyte |
Emerging importance of nutrient transporter-mediated DDIs |
|
Avner Schlessinger, Mount Sinai School of Medicine |
Inhibitor Discovery for the Human GLUT1 from Homology Modelling and Virtual Screening |
Not Available |
Par Matsson, Uppsala University |
Computational modelling to predict the functions and impact of drug transporters |
Not Available |
Aleksandra Galetin, University of Manchester |
PBPK modelling of renal impairment – what is missing? |
|
Mikko Niemi, University of Helsinki |
Massively parallel sequencing of drug transporters - SLCO1B1 and beyond |
Not Available |
Kathy Giacomini, University of California San Francisco |
Genomewide Studies Reveal Transporters as Determinants of Drug Response |
|
Ana Pajor, University of California San Diego |
Na+/citrate transporter [SLC13A5] variants in epilepsy and developmental delay |
|
Hiroyuki Kusuhara, University of Tokyo |
Endogenous biomarkers for renal transporters |
|
Yurong Lai, Gilead Sciences |
Endogenous biomarkers for OATP1B: preclinical to clinical translation |
|
Mitchell Taub, Boehringer Ingelheim |
Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
|
Lei Zhang, U.S. Food and Drug Administration |
Regulatory Science Perspectives on Transporter-Mediated Drug-Drug Interactions |
|
Eva Gil Berglund, Medical Products Agency (Sweden) |
An European Perspective |
|
Xiaoyan Chu, Merck |
Evaluation of Dabigatrin Etexilate as a Clinical Probe for P-gp Inhibition: Comparison with Digoxin |
Not Available |
Justin Lutz, Gilead Sciences |
Induction: Drug Transporters versus Enzymes |
|
Imad Hanna, Novartis |
Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically-Based Pharmacokinetic Model |
|
Kari Morrissey, Genentech |
IVIVE of Transporter-Mediated Clinical Drug-Drug Interactions in Industry – An Update from the IQ Transporter Working Group |
Name |
Affiliation |
Kim Brouwer |
University of North Carolina, Chapel Hill |
Aleksandra Galetin |
University of Manchester |
Kathy Giacomini |
University of California San Francisco |
Shiew-Mei Huang |
U.S. Food and Drug Administration |
Par Matsson |
Uppsala University |
Nilay Thakkar |
University of North Carolina, Chapel Hill |
Donald Tweedie |
Merck |
Maciej Zamek-Gliszczynski |
GlaxoSmithKline |
Lei Zhang |
U.S. Food and Drug Administration |